Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Caladrius Biosciences

Caladrius Biosciences?uq=kzBhZRuG
1980 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
CLBS STOCK SYMBOL
4 INVESTMENTS
$5.05 SHARE PRICE (As of Friday Closing)
Description

Operator of cellular therapy firm. The company's services include product and process development related to cell therapy, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as consulting and regulatory support.

Formerly Known As
Phase III Medical, Corniche Group, Neostem
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 106 Allen Road
  • 4th Floor
  • Basking Ridge, NJ 07920
  • United States

+1 (908) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Caladrius Biosciences’s full profile, request a free trial.

Caladrius Biosciences Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$2.66 - $8.64 $51.2M $5.27 $3.06 327K 9.7M

Caladrius Biosciences Financials Summary

In Thousands,
USD
TTM
31-Mar-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 549 43,911 19,147 51,219
Revenue 22,488
EBITDA (25,464) (26,948) (29,028) (93,439)
Net Income 27,445 22,979 (32,656) (80,886)
Total Assets 56,717 63,376 53,514 57,205
Total Debt 92 159 6,374 16,776
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Caladrius Biosciences Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Caladrius Biosciences‘s full profile, request access.

Request full access to PitchBook

Caladrius Biosciences Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 0000 00 08-May-2014 000000000000000000 0000 Biotechnology
00000000 25-Jul-2011 0000000000 00.00 Biotechnology
000 20-Jan-2011 000000000000000000 Biotechnology 00000 00000 00.0
StemCell Technologies 14-Nov-2007 Merger/Acquisition Biotechnology 00000 00000 00
To view this company’s complete investment and acquisition history, request access »

Caladrius Biosciences Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000 20-Jan-2011 000000000000000000 Completed
  • 000000000 00000000
To view this company’s complete exits history, request access »

Caladrius Biosciences Subsidiaries (1)

Company Name Industry Location Founded
00000000 000000000 Biotechnology Vancouver, Canada 0000
To view this company’s complete subsidiary history, request access »

Caladrius Biosciences Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Caladrius Biosciences‘s full profile, request access.

Request full access to PitchBook

Caladrius Biosciences Executive Team (16)

Name Title Board
Seat
Contact
Info
David Mazzo Ph.D Chief Executive Officer & Director
Joseph Talamo Senior Vice President & Chief Financial Officer
Peter Traber Director
Kenneth Berger Ph.D NeoStem
Adel Nada Vice President, Immunotherapy

7 Former Executives

You’re viewing 5 of 16 executives. Get the full list »

Caladrius Biosciences Board Members (7)

Name Representing Role Since Contact
Info
0000 000000000 Self Director, Chairman of Audit Committee 000 0000
000000 000000000 Self Director, Member of Audit, Governance and Nominating Committee 000 0000
0000000 000000 00 Self Director, Chairman of Compensation Committee & Member, Audit Committee 000 0000
000000 00000 00 Self Board Member 000 0000
000000 00000 Self Lead Director & Chairman, Governance & Nominating Committee 000 0000

2 Former Board Members

You’re viewing 5 of 7 board members. Get the full list »